查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2152296

肌萎縮側索硬化症 (ALS) 治療市場規模、佔有率和趨勢分析報告：按治療方法、類型、分銷管道、地區和細分市場預測 (2026–2033)

Amyotrophic Lateral Sclerosis Treatment Market Size, Share & Trends Analysis Report By Treatment (Medication, Stem Cell Therapy), By Type (Sporadic ALS, Familial ALS), By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

預計到 2025 年，全球肌萎縮側索硬化症 (ALS) 治療市場價值將達到 7.467 億美元，到 2026 年將成長至 7.9 億美元，到 2033 年將成長至 11.723 億美元，2026 年至 2033 年的複合年成長率為 5.8%。

北美是市場的主要驅動力，預計到 2025 年將佔銷售額的 37.5%。肌萎縮側索硬化症 (ALS) 的發病率和盛行率不斷上升，尤其是影響大量患者的散發性 ALS，是市場成長的主要驅動力。

此外，老年人口的成長是肌萎縮側索硬化症（ALS）的主要風險因素之一，也導致了病例數的增加。隨著人口老化，對有效治療方法的需求預計將會增加。

對標靶治療和緩解疾病療法研發的日益重視有望推動肌萎縮側索硬化症（ALS）治療領域的創新。例如，2025年12月，渤健公司宣布，其3期VALOR試驗及其開放標籤擴展試驗的長期結果顯示，早期使用QALSODY（托福生）治療可延緩SOD1相關ALS患者的臨床功能、呼吸功能和肌肉力量的下降。這項發現凸顯了精準醫療和基因標靶治療在改善ALS患者預後方面取得的快速進展。

認知度的提高和診斷率的提升也是市場成長的關鍵促進因素。患者和醫療專業人員對肌萎縮側索硬化症（ALS）及其治療方案的認知度不斷提高，導致診斷率上升，進而推動了ALS藥物的需求。這種認知度的提高有望促進早期診斷和治療，從而改善患者預後並加速市場成長。

有利的保險報銷政策和不斷拓展的分銷管道也在推動市場成長。在北美等地區，針對肌萎縮側索硬化症（ALS）治療的有利保險報銷政策，使得患者更容易獲得這些療法，從而推動了市場成長。透過醫院藥局、零售藥局和線上管道，ALS藥物的供應量增加，擴大了病患的用藥途徑，並促進了市場成長。隨著市場的不斷發展，這些因素預計將進一步推動市場成長和擴張。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：肌萎縮側索硬化症（ALS）治療市場：變數、趨勢和範圍

  • 市場概況及未來展望
  • 市場規模和成長前景
  • 市場動態
  • 肌萎縮側索硬化症 (ALS) 治療市場分析工具

第4章：肌萎縮側索硬化症（ALS）治療市場：按治療類型分類的估計和趨勢分析

  • 肌萎縮側索硬化症 (ALS) 治療市場：按治療方法分類的趨勢，2025 年和 2033 年
  • 藥物
    • Riluzole
    • Edaravone
    • 其他
  • 幹細胞療法
  • 其他

第5章：肌萎縮側索硬化症（ALS）治療市場：按類型分類的估算和趨勢分析

  • 肌萎縮側索硬化症 (ALS) 治療市場：按類型分類的趨勢分析，2025 年和 2033 年
  • 散發性肌萎縮性側索硬化症
  • 遺傳性肌萎縮性側索硬化症

第6章：肌萎縮側索硬化症（ALS）治療市場：按分銷管道分類的估算和趨勢分析

  • 肌萎縮側索硬化症 (ALS) 治療市場：按分銷管道分類的趨勢分析，2025 年和 2033 年
  • 醫院藥房
  • 零售藥房
  • 其他

第7章：肌萎縮側索硬化症（ALS）治療市場：區域估算與趨勢分析

  • 2025 年和 2033 年肌萎縮側索硬化症 (ALS) 治療市場的區域市場佔有率
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第8章 競爭情勢

  • 主要市場參與企業近期趨勢及影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Mitsubishi Tanabe Pharma Corporation（Mitsubishi Chemical Group Corporation）
    • Biogen
    • BrainStorm Cell Limited
    • Amylyx Pharmaceuticals, Inc.
    • Ionis Pharmaceuticals, Inc.
    • Sanofi
    • Otsuka Pharmaceutical Co., Ltd.
    • F. Hoffmann-La Roche Ltd
    • AB Science
    • Sun Pharmaceutical Industries Ltd.
    • Orion Corporation
    • CORESTEMCHEMON Inc.
簡介目錄
Product Code: GVR-4-68038-001-9

The global amyotrophic lateral sclerosis treatment market size was valued at USD 746.7 million in 2025 and is projected to grow from USD 790.0 million in 2026 to USD 1,172.3 million in 2033, at a CAGR of 5.8% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 37.5% in 2025. The increasing incidence and prevalence of amyotrophic lateral sclerosis (ALS), particularly sporadic ALS, which affects a large number of patients, is a major driver of market growth.

Furthermore, the growing geriatric population, a key risk factor for ALS, is also contributing to the rise in cases. As the population ages, the demand for effective treatment options is likely to increase.

The growing focus on developing targeted therapies and disease-modifying treatments is expected to drive innovation in the ALS treatment landscape. For instance, in December 2025, Biogen announced that long-term results from the Phase 3 VALOR study and its open-label extension demonstrated that early treatment with QALSODY (tofersen) was associated with a slower decline in clinical function, breathing, and muscle strength in patients with SOD1-associated ALS. The findings highlight the increasing progress in precision medicine and gene-targeted therapies aimed at improving outcomes for ALS patients.

Increased awareness and diagnosis are also key drivers of market growth. Rising awareness among patients and healthcare professionals about ALS and available treatment options is boosting diagnosis rates and driving demand for ALS drugs. This increased awareness is likely to lead to earlier diagnosis and treatment, resulting in better patient outcomes and increased market growth.

Favorable reimbursement policies and expansion of distribution channels are also supporting market growth. In regions such as North America, favorable reimbursement policies for ALS treatments are facilitating access to these therapies and driving market growth. The increasing availability of ALS drugs through hospital pharmacies, retail pharmacies, and online channels is broadening patient access and boosting market growth. As the market continues to evolve, these factors are likely to drive further growth and expansion.

Amyotrophic Lateral Sclerosis Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global amyotrophic lateral sclerosis treatment market report by treatment, type, distribution channel, and region:

  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)

Medication

    • Riluzole
    • Edaravone
    • Others

Stem Cell Therapy

Others

  • Type Outlook (Revenue, USD Million, 2021 - 2033)

Sporadic ALS

Familial ALS

  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

Hospital Pharmacies

Retail Pharmacies

Others

  • Regional Outlook (Revenue, USD Million, 2021 - 2033)

North America

    • U.S.
    • Canada
    • Mexico

Europe

    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway

Asia Pacific

    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand

Latin America

    • Brazil
    • Argentina

Middle East & Africa

    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Amyotrophic Lateral Sclerosis Treatment Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Amyotrophic Lateral Sclerosis Treatment Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Amyotrophic Lateral Sclerosis Treatment Market: Treatment Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Amyotrophic Lateral Sclerosis Treatment Market: Treatment Movement Analysis, 2025 & 2033 (USD Million)
  • 4.3. Medication
    • 4.3.1. Medication Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.2. Riluzole
      • 4.3.2.1. Riluzole Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.3. Edaravone
      • 4.3.3.1. Edaravone Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.4. Others
      • 4.3.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Stem Cell Therapy
    • 4.4.1. Stem Cell Therapy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Others
    • 4.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Amyotrophic Lateral Sclerosis Treatment Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Amyotrophic Lateral Sclerosis Treatment Market: Type Movement Analysis, 2025 & 2033 (USD Million)
  • 5.3. Sporadic ALS
    • 5.3.1. Sporadic ALS Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Familial ALS
    • 5.4.1. Familial ALS Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Amyotrophic Lateral Sclerosis Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Amyotrophic Lateral Sclerosis Treatment Market: Distribution Channel Movement Analysis, 2025 & 2033 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Amyotrophic Lateral Sclerosis Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Amyotrophic Lateral Sclerosis Treatment Market Share, By Region, 2025 & 2033 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group Corporation)
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/Strategic Initiatives
    • 8.4.2. Biogen
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/Strategic Initiatives
    • 8.4.3. BrainStorm Cell Limited
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/Strategic Initiatives
    • 8.4.4. Amylyx Pharmaceuticals, Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/Strategic Initiatives
    • 8.4.5. Ionis Pharmaceuticals, Inc.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/Strategic Initiatives
    • 8.4.6. Sanofi
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/Strategic Initiatives
    • 8.4.7. Otsuka Pharmaceutical Co., Ltd.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/Strategic Initiatives
    • 8.4.8. F. Hoffmann-La Roche Ltd
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/Strategic Initiatives
    • 8.4.9. AB Science
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/Strategic Initiatives
    • 8.4.10. Sun Pharmaceutical Industries Ltd.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/Strategic Initiatives
    • 8.4.11. Orion Corporation
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/Strategic Initiatives
    • 8.4.12. CORESTEMCHEMON Inc.
      • 8.4.12.1. Participant's Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Product Benchmarking
      • 8.4.12.4. Recent Developments/Strategic Initiatives